3D Imaging for Aesthetic Pharma and Device Companies

Aesthetic pharma and device companies face the same documentation problem as their customer clinics, only at scale. A dermal filler adds volume; a contouring device changes shape; a skin product changes texture or tone. Yet the evidence that reaches doctors and patients is often a handful of photos with all the distortions of 2D imaging. Phone-based 3D imaging gives the industry a way to make results measurable across many clinics.

The industry's measurement gap

• Doctors want proof they can relate to their own patients, not just trial summaries.
• Patients want to see change on faces like theirs.
• Medical and marketing teams need evidence that is consistent and defensible.
• Rig-based imaging has been limited to a few large centres because of cost and fixed rooms.

India adds its own context. Its medical aesthetics market is growing quickly; MarketsandMarkets estimates it at about USD 607 million in 2025, heading towards USD 1.3 billion by 2031. Much of that growth is outside the largest metro centres, where imaging rigs rarely exist.

Use cases for pharma and device companies

1. Doctor engagement programmes

Equip participating clinics with phone-based 3D imaging so they can show patients measured results with your product. This creates a tangible value-add beyond the product and builds loyalty among prescribers. Launches at doctor events, with QR-based onboarding, are a common format.

2. Measured outcome showcases

With proper patient consent, aggregate measured outcomes, such as volume change at two weeks and longevity at later intervals, to show how results look in Indian patients. See dermal filler volume measurement.

3. Observational studies and post-marketing data

3D scans collected under a defined protocol can support observational research. This needs ethics approval, a clear protocol and consent, and careful framing of claims. Measurement tools describe shape; they do not establish clinical efficacy on their own.

4. Training and medical education

Rotatable 3D cases help trainers explain anatomy, placement and outcomes better than flat images.

5. Device outcome visibility

For body contouring and skin-tightening devices, measured contour change helps clinics show patients what a course achieved. See body contouring measurement.

Designing a programme that doctors value

Programmes built around a measurement tool work best when the tool helps the doctor first and the brand second. A few design principles:

• Make it useful in every consultation, not just with your product. Doctors adopt tools that help their whole practice.
• Keep onboarding light: a phone, an app and a short training session, rather than equipment and installation.
• Respect data boundaries: patient data belongs to the clinic as data fiduciary. Any aggregated outcome data shared with the company needs a clear legal basis, consent and de-identification.
• Agree what will be measured before the programme starts, such as volume change at a fixed interval, so results are comparable across clinics.
• Close the loop with participating doctors by sharing aggregate, de-identified findings with them.

Handled this way, a measurement programme becomes a long-term relationship asset rather than a one-off promotion.

What to look for in a partner

• Published accuracy against a clinical reference system. See how accurate is smartphone 3D face scanning.
• Data protection: consent per scan, encryption, data in India, no use of data to train models, DPDP-ready contracts. See the DPDP Act and patient photos.
• Scalable pricing for many clinics.
• Integration options so data flows into your systems.
• Clear separation between measurement and any product claims.

How Edebo works with industry partners

Edebo serves dermal filler and injectable makers, aesthetic device manufacturers and clinic software platforms alongside clinics. The clinics and platforms plan, at ₹25,000 a month, includes 5,000 scans, up to 10 practitioner profiles with four devices each, a scanning and reconstruction API, an organisation dashboard with role controls, and white-label options, with falling per-scan rates at higher volumes.

Edebo is a measurement and visualisation tool, not a diagnostic device, and that boundary keeps partner programmes on firm ground: the scan measures change; clinical and regulatory teams decide what claims are appropriate.

For platform integrations, read integrating 3D imaging with clinic CRM and EMR.

Edebo is a measurement and visualisation tool, not a diagnostic device. Clinical decisions remain with the treating practitioner.